Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Yield10 begins 2020 field test program to evaluate Camelina, canola traits » 08:38
06/17/20
06/17
08:38
06/17/20
08:38
YTEN

Yield10 Bioscience

$6.20 /

-0.14 (-2.21%)

Yield10 Bioscience…

Yield10 Bioscience announced it has begun its 2020 Field Test Program based on the recent completion of planting at all sites contracted for the trials in the United States and Canada. Yield10's 2020 Field Test Program is designed to evaluate several novel traits in Camelina and canola and the Company expects to harvest the plants and begin reporting data from the field tests in the fourth quarter of 2020. A summary of the 2020 Field Test Program: Camelina/C3004: C3004 is a trait designed to increase seed yield that has shown promise in previous greenhouse and growth chamber experiments. Camelina/CRISPR E3902: E3902 is a CRISPR genome-edited trait designed to boost oil content. This line demonstrated positive results in 2019 field tests. Camelina/CRISPR C3007: C3007 is a CRISPR genome-edited trait designed to boost oil content. This is the first season of field testing the trait. Camelina/C3014 and C3015: Yield10 has designed a novel trait and reprogrammed Camelina to produce PHA biomaterial as a third seed product. This is the first season of field tests for the trait. Canola/C3004: C3004 is a trait designed to increase seed yield. This is the first season of field testing the trait in canola. Canola/C3003: Yield10 will grow 14 new canola/C3003 commercial quality lines for seed bulk up in the field in 2020 that the Company plans to field test in 2021. C3003 is a seed yield trait. In the field tests of its novel traits in Camelina and canola, Yield10 is monitoring key agronomic and growth parameters of the plants throughout the growth period. Yield10 also plans to evaluate seed yield, oil content, PHA content and/or other parameters of the traits as appropriate after seed harvest. The field tests are designed to generate data on the performance of the novel traits under field conditions and to advance the development of the traits toward commercialization. The program will also generate field grown seed for subsequent field studies.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$6.20 /

-0.14 (-2.21%)

YTEN Yield10 Bioscience
$6.20 /

-0.14 (-2.21%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
YTEN Yield10 Bioscience
$6.20 /

-0.14 (-2.21%)

YTEN Yield10 Bioscience
$6.20 /

-0.14 (-2.21%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 19:11
05/14/20
05/14
19:11
05/14/20
19:11
YTEN

Yield10 Bioscience

$4.92 /

-0.02 (-0.40%)

, OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

, DENN

Denny's

$8.77 /

-0.035 (-0.40%)

, ACB

Aurora Cannabis

$6.61 /

+0.79 (+13.57%)

, AEYE

AudioEye

$8.88 /

+0.71 (+8.69%)

, NEWR

New Relic

$58.22 /

+1.62 (+2.86%)

, DDS

Dillard's

$22.94 /

-1.15 (-4.77%)

, AMAT

Applied Materials

$54.51 /

+2.98 (+5.78%)

, GLOB

Globant

$111.38 /

+3.1 (+2.86%)

, OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CODX

Co-Diagnostics

$22.19 /

-1.2 (-5.13%)

, FTCH

Farfetch

$15.94 /

+0.35 (+2.25%)

, CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

, ETON

Eton Pharmaceuticals

$5.20 /

+0.03 (+0.58%)

, AUPH

Aurinia Pharmaceuticals

$17.39 /

-0.19 (-1.08%)

, VVI

Viad

$16.65 /

+0.71 (+4.45%)

, TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
DENN Denny's
$8.77 /

-0.035 (-0.40%)

04/08/20 Oppenheimer
Denny's price target lowered to $13 from $27 at Oppenheimer
04/01/20 SunTrust
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 SunTrust
Denny's upgraded to Buy from Hold at SunTrust
03/20/20 Stephens
Denny's price target lowered to $12 from $19 at Stephens
ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

05/13/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$22 from C$2.75 at Cantor Fitzgerald
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

10/24/19 National Securities
AudioEye resumed with a Buy at National Securities
05/31/19 B. Riley FBR
AudioEye selloff brings 'compelling' entry point, syays B. Riley FBR
NEWR New Relic
$58.22 /

+1.62 (+2.86%)

04/27/20 Needham
New Relic price target lowered to $74 from $108 at Needham
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight amid weaker backdrop at Morgan Stanley
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
04/06/20 Rosenblatt
New Relic initiated with a Neutral at Rosenblatt
DDS Dillard's
$22.94 /

-1.15 (-4.77%)

05/07/20 Deutsche Bank
Dillard's price target lowered to $18 from $36 at Deutsche Bank
04/30/20 Wedbush
Dillard's price target lowered to $25 from $63 at Wedbush
01/24/20 Odeon Capital
Dillard's initiated with a Sell at Odeon Capital
11/11/19 Deutsche Bank
L Brands downgraded to Hold from Buy at Deutsche Bank
AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

05/12/20 Susquehanna
Applied Materials fundamentals strong ahead of results, says Susquehanna
05/11/20 Cowen
Applied Materials sales trajectory has positive slope, says Cowen
05/08/20 Wells Fargo
Applied Materials price target raised to $60 from $50 at Wells Fargo
04/14/20 Deutsche Bank
Applied Materials share underperformance unwarranted, says Deutsche Bank
GLOB Globant
$111.38 /

+3.1 (+2.86%)

04/29/20 Goldman Sachs
Globant price target lowered to $130 from $165 at Goldman Sachs
04/16/20 Wedbush
Globant price target lowered to $120 from $150 at Wedbush
03/10/20 KeyBanc
Globant downgraded to Sector Weight from Overweight at KeyBanc
02/21/20 Cantor Fitzgerald
Globant price target raised to $120 from $97 at Cantor Fitzgerald
OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
03/30/20 Wells Fargo
Farfetch downgraded to Underweight from Equal Weight at Wells Fargo
02/28/20 KeyBanc
Farfetch price target lowered to $17 from $20 at KeyBanc
11/15/19 Credit Suisse
Farfetch price target lowered to $17 from $22 at Credit Suisse
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

03/30/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $26 from $23 at H.C. Wainwright
01/28/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $23 from $21 at H.C. Wainwright
10/23/19 H.C. Wainwright
Eton Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
09/20/19
Fly Intel: Top five analyst initiations
AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

  • 15
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

Earnings
Yield10 Bioscience reports Q1 EPS ($2.12), consensus ($1.97) » 16:20
05/14/20
05/14
16:20
05/14/20
16:20
YTEN

Yield10 Bioscience

$4.95 /

+0.01 (+0.20%)

Reports Q1 revenue $179K,…

Reports Q1 revenue $179K, consensus $170K.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.95 /

+0.01 (+0.20%)

YTEN Yield10 Bioscience
$4.95 /

+0.01 (+0.20%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
YTEN Yield10 Bioscience
$4.95 /

+0.01 (+0.20%)

Hot Stocks
Yield10 Bioscience to hold Annual Meeting of Stockholders virtually » 09:07
05/06/20
05/06
09:07
05/06/20
09:07
YTEN

Yield10 Bioscience

$5.67 /

-0.05 (-0.87%)

Yield10 Bioscience…

Yield10 Bioscience announced a change in the format of its Annual Meeting of Shareholders from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic and to support the health and well-being of the Company's shareholders, employees and their families. As previously announced, the Annual Meeting will be held on Tuesday, May 19, 2020, at 9:30 a.m. EDT.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$5.67 /

-0.05 (-0.87%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
Hot Stocks
Yield10 obtains response from USDA-APHIS on regulatory status of C3007 trait » 08:54
04/27/20
04/27
08:54
04/27/20
08:54
YTEN

Yield10 Bioscience

$5.25 /

-0.05 (-0.94%)

Yield10 Bioscience…

Yield10 Bioscience announced that it has obtained a positive response from USDA-APHIS's Biotechnology Regulatory Services for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10's submission along with the USDA-APHIS BRS response is posted on the USDA's website. In January 2020, Yield10 submitted an "Am I Regulated?" letter to the BRS, requesting confirmation of the regulatory status for Camelina plant lines containing the Company's novel, CRISPR genome-edited C3007 trait. The positive USDA-APHIS response came in the form of a published letter indicating that the plant lines do not meet the definition of a regulated article under 7 CFR Part 340. This clarification of the regulatory status under USDA-APHIS guidelines accelerates the path for Yield10 to conduct field trials of the CRISPR genome-edited C3007 plants in the United States in the 2020 growing season. The plant lines may still be subject to regulation by the U.S. Environmental Protection Agency or the U.S. Food and Drug Administration. The ability to increase oil content in specialty oilseed crops like Camelina has the potential to make a significant impact in the supply of omega fatty acid containing oils, to human nutrition and aquaculture feed markets. Further, the continued analysis of C3007 and its role as a key regulator of oil content in Camelina may also enable this trait to be used to increase production of edible oils in other major oilseed crops such as soybean and canola. Yield10 licensed C3007 from the University of Missouri in 2018. The protein encoded by C3007, also known as BADC, is a novel regulator of the enzyme acetyl-CoA carboxylas, the key enzyme for producing fatty acids for oil biosynthesis. In pilot studies conducted by MU researchers, reducing activity of the protein encoded by C3007 resulted in significantly increased oil content in seeds. Yield10 researchers have successfully used CRISPR to inactivate a number of the C3007 gene copies in Camelina and have seen clear evidence of increased oil content in some lines in laboratory studies. The use of CRISPR to deploy the trait may enable an expedited timeline for development and commercialization within the U.S. market. The CRISPR genome-edited C3007 trait could deliver significant economic value by changing the value equation for the commercialization of identity preserved, specialty oilseed crops where the key value-driver is oil content with improved nutritional profiles for human consumption or for aquaculture feed or industrial markets. These traits may also be used to increase production of edible oils in major oilseed crops such as soybean and canola.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$5.25 /

-0.05 (-0.94%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
Over a quarter ago
On The Fly
Fly Intel: After-Hours Movers » 19:13
04/01/20
04/01
19:13
04/01/20
19:13
PVH

PVH Corp.

$32.53 /

-5.08 (-13.51%)

, IO

ION Geophysical

$1.16 /

-0.13 (-10.08%)

, CRTO

Criteo

$7.55 /

-0.39 (-4.91%)

, FTI

TechnipFMC

$6.54 /

-0.21 (-3.11%)

, YTEN

Yield10 Bioscience

$4.02 /

+0.26 (+6.91%)

, AFMD

Affimed N.V.

$1.60 /

+0.02 (+1.27%)

, RRTS

Roadrunner

$2.55 /

+ (+0.00%)

, ETH

Ethan Allen

$9.45 /

-0.77 (-7.53%)

, MUR

Murphy Oil

$5.60 /

-0.52 (-8.50%)

, ARNC

Arconic

$6.83 /

+ (+0.00%)

, DHT

DHT Holdings

$7.77 /

+0.09 (+1.17%)

, GMLP

Golar LNG Partners

$3.17 /

-0.2 (-5.93%)

, NVTA

Invitae

$11.72 /

-1.945 (-14.24%)

, SHOP

Shopify

$384.67 /

-33.65 (-8.04%)

, NVRO

Nevro

$89.51 /

-10.42 (-10.43%)

, PCAR

Paccar

$60.17 /

-1.05 (-1.72%)

, CSII

Cardiovascular Systems

$35.13 /

+0.03 (+0.09%)

Check out this…

Open Full Text

ShowHide Related Items >><<
PVH PVH Corp.
$32.53 /

-5.08 (-13.51%)

03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
03/13/20 Deutsche Bank
PVH Corp. downgraded to Hold from Buy at Deutsche Bank
02/03/20 BMO Capital
PVH Corp. initiated with a Market Perform at BMO Capital
11/27/19
Fly Intel: Top five analyst downgrades
IO ION Geophysical
$1.16 /

-0.13 (-10.08%)

03/09/20 Evercore ISI
ION Geophysical downgraded to Underperform from Outperform at Evercore ISI
CRTO Criteo
$7.55 /

-0.39 (-4.91%)

04/01/20 SunTrust
SunTrust says Criteo pulling guidance not surprising
03/30/20 BMO Capital
Criteo upgraded to Outperform from Market Perform at BMO Capital
03/30/20 BMO Capital
Criteo upgraded to Outperform from Market Perform at BMO Capital
02/12/20 Nomura Instinet
Criteo price target lowered to $14 from $19 at Nomura Instinet
FTI TechnipFMC
$6.54 /

-0.21 (-3.11%)

03/27/20 Piper Sandler
TechnipFMC downgraded to Neutral from Overweight at Piper Sandler
03/26/20 Berenberg
TechnipFMC upgraded to Buy from Hold at Berenberg
03/19/20 Barclays
TechnipFMC upgraded to Overweight from Equal Weight at Barclays
03/16/20 Tudor Pickering
TechnipFMC downgraded to Hold from Buy at Tudor Pickering
YTEN Yield10 Bioscience
$4.02 /

+0.26 (+6.91%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
AFMD Affimed N.V.
$1.60 /

+0.02 (+1.27%)

RRTS Roadrunner
$2.55 /

+ (+0.00%)

ETH Ethan Allen
$9.45 /

-0.77 (-7.53%)

MUR Murphy Oil
$5.60 /

-0.52 (-8.50%)

03/25/20 Piper Sandler
Murphy Oil price target lowered to $3 from $34 at Piper Sandler
03/20/20 Wells Fargo
Murphy Oil can navigate turbulent environment, says Wells Fargo
03/20/20 Wells Fargo
Correction: Murphy Oil upgraded to Overweight at Wells Fargo
03/20/20 Wells Fargo
Murphy Oil upgraded to Overweight from Equal Weight at Wells Fargo
ARNC Arconic
$6.83 /

+ (+0.00%)

04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
02/18/20 Argus
Arconic upgraded to Buy from Hold at Argus
02/18/20 Argus
Arconic upgraded to Buy from Hold at Argus
DHT DHT Holdings
$7.77 /

+0.09 (+1.17%)

03/09/20
Fly Intel: Top five analyst upgrades
03/09/20 DNB Markets
DHT Holdings downgraded to Hold from Buy at DNB Markets
03/09/20 Stifel
DHT Holdings upgraded to Buy from Hold at Stifel
04/24/19 Stifel
U.S. sanctions on Iran could benefit crude tankers, says Stifel
GMLP Golar LNG Partners
$3.17 /

-0.2 (-5.93%)

02/26/20 Odeon Capital
Golar LNG Partners upgraded to Hold from Sell at Odeon Capital
02/26/20 Evercore ISI
Golar LNG Partners upgraded to Outperform from In Line at Evercore ISI
02/04/20 Odeon Capital
Golar LNG Partners downgraded to Sell from Hold at Odeon Capital
01/23/20 Evercore ISI
Evercore downgrades GasLog Partners, Golar LNG Partners on balance sheet 'holes'
NVTA Invitae
$11.72 /

-1.945 (-14.24%)

02/20/20 Cowen
Invitae price target raised to $30 from $20 at Cowen
01/28/20 Cowen
More flexible Medicare coverage for NGS a positive for Invitae, says Cowen
11/27/19 Oppenheimer
Invitae 2020 guidance could be set conservatively, says Oppenheimer
07/12/19 Benchmark
Invitae price target raised to $26 after Jungla deal announcement at Benchmark
SHOP Shopify
$384.67 /

-33.65 (-8.04%)

04/01/20 Baird
Shopify suspending guidance 'not a surprise,' says Baird
04/01/20 Baird
Shopify price target lowered to $475 from $590 at Baird
03/23/20 KeyBanc
Shopify price target lowered to $500 from $575 at KeyBanc
03/23/20 KeyBanc
KeyBanc most positive near-term on Shopify, PayPal amid COVID-19 outbreak
NVRO Nevro
$89.51 /

-10.42 (-10.43%)

03/04/20 Citi
Nevro initiated with a Buy at Citi
02/26/20 SVB Leerink
Nevro price target raised to $158 from $146 at SVB Leerink
02/26/20 Canaccord
Nevro momnetum should continue to build, Canaccord upgrades to Buy
02/26/20 Wells Fargo
Nevro price target raised to $158 from $144 at Wells Fargo
PCAR Paccar
$60.17 /

-1.05 (-1.72%)

03/27/20 Wolfe Research
Paccar upgraded to Peer Perform from Underperform at Wolfe Research
03/13/20 Piper Sandler
Piper tells investors to own 'built for this environment' Paccar
03/09/20 Cowen
Cowen upgrades Paccar to Market Perform on 'flight to quality'
03/09/20 Cowen
Paccar upgraded to Market Perform from Underperform at Cowen
CSII Cardiovascular Systems
$35.13 /

+0.03 (+0.09%)

10/18/19 Guggenheim
Guggenheim starts 'underestimated' Cardiovascular Systems at Buy
10/17/19 Guggenheim
Cardiovascular Systems initiated with a Buy at Guggenheim
08/07/19 Lake Street
Cardiovascular Systems price target raised to $60 from $50 at Lake Street
07/16/19 Stifel
Cardiovascular Systems downgraded to Hold at Stifel on valuation
  • 02
    Apr
  • 02
    Apr
Syndicate
Yield10 Bioscience files $25M mixed securities shelf  17:35
04/01/20
04/01
17:35
04/01/20
17:35
YTEN

Yield10 Bioscience

$4.02 /

+0.26 (+6.91%)

 
ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.02 /

+0.26 (+6.91%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
Hot Stocks
Yield10 Bioscience announces results of 2019 field test program » 16:04
03/19/20
03/19
16:04
03/19/20
16:04
YTEN

Yield10 Bioscience

$4.50 /

+0.55 (+13.92%)

Yield10 Bioscience…

Yield10 Bioscience announced the results from field tests conducted in the 2019 growing season in the United States and Canada. Data from the field tests suggest that novel traits can be successfully deployed in the oil biosynthesis pathway using CRISPR genome-editing technology to boost seed oil content in Camelina. Additional results recorded in the field studies suggest that the activity and expression of trait C3004 can boost photosynthetic efficiency in Camelina, an outcome that supports further field work in 2020. Permitting is underway to continue the testing of these traits and for testing of several traits in Camelina and canola in 2020 field tests in the U.S. and Canada, with planting expected to begin in Q2. Yield10 is developing Camelina as a platform crop to evaluate new yield trait leads identified using our GRAIN platform. The Company is also developing Camelina as an oilseed crop for nutritional oils for food and feed applications and future bioproducts such as PHA biomaterials. Boosting seed yield and oil content will make Camelina an increasingly attractive crop for farmers. Yield10 is also continuing to develop C3003 and C3004 as performance seed yield traits in Camelina, canola, and corn, and has formed relationships with major seed companies to test these traits in other commercially important crops.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.50 /

+0.55 (+13.92%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
Hot Stocks
Yield10 Bioscience achieves milestones in early development program in corn » 08:48
03/10/20
03/10
08:48
03/10/20
08:48
YTEN

Yield10 Bioscience

$4.85 /

-0.87 (-15.21%)

Yield10 Bioscience…

Yield10 Bioscience announced that it achieved key milestones in an early development program in corn to evaluate novel seed yield traits. Corn is the highest value commercial crop grown in the United States. The Company's corn program began in early 2019, centered around the successful deployment of novel traits discovered by Yield10 into corn by a major third-party agriculture company partner. With this phase of the program complete, Yield10 recently contracted an additional third-party agriculture company to create homozygous and hybrid corn lines, bulk-up seed, and conduct field testing of the novel traits in corn to evaluate the impact on seed yield. The yield traits in the corn development program include C3003, C3004, and C3011, as well as the transcription factors C4001, C4002, and C4003.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.85 /

-0.87 (-15.21%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
Hot Stocks
Yield10 Bioscience appoints Sherri Brown to board of directors » 08:40
02/13/20
02/13
08:40
02/13/20
08:40
YTEN

Yield10 Bioscience

$7.43 /

-0.585 (-7.30%)

Yield10 Bioscience…

Yield10 Bioscience announced that Sherri M. Brown, Ph.D. was appointed to the Company's Board of Directors effective February 11, 2020. In connection with her appointment, Dr. Brown will serve as chair of a newly formed Science and Technology Committee of the Board. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company. Since 2017, Dr. Brown has served as the managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. The Company also announced today that Peter Kellogg has stepped down from the Board of Directors, effective February 11, 2020. Further, the Company announced that Board member Anthony Sinskey, Ph.D. has been appointed to serve as a member of the Audit Committee of the Board, effective February 11, 2020.

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$7.43 /

-0.585 (-7.30%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.